Loading...
Loading...
TPST| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 10.9M |
| Operating I/L | -10.9M |
| Other Income/Expense | 0.1M |
| Interest Income | 0.2M |
| Pretax | -10.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -10.9M |
Tempest Therapeutics Inc. is a clinical-stage oncology company specializing in the development of small molecule therapeutics for cancer treatment. The company's primary focus is on its two clinical programs: TPST-1495, a dual antagonist of EP2 and EP4 receptors of prostaglandin E2, currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, also in a Phase 1 trial in solid tumors. Additionally, the company is developing TREX-1, a key cellular enzyme that regulates the innate immune response in tumors, showcasing its commitment to innovative cancer therapies.
